114 filings
15-12G
GRCL
Gracell Biotechnologies Inc
4 Mar 24
Securities registration termination
12:22pm
EFFECT
GRCL
Gracell Biotechnologies Inc
28 Feb 24
Notice of effectiveness
12:15am
EFFECT
GRCL
Gracell Biotechnologies Inc
28 Feb 24
Notice of effectiveness
12:15am
S-8 POS
GRCL
Gracell Biotechnologies Inc
26 Feb 24
Registration of securities for employees (post-effective amendment)
5:28pm
POS AM
GRCL
Gracell Biotechnologies Inc
26 Feb 24
Prospectus update (post-effective amendment)
5:28pm
POS AM
sc38yd82 2rc5w8q
26 Feb 24
Prospectus update (post-effective amendment)
5:26pm
S-8 POS
emzi7htqr9hztre9c9xy
26 Feb 24
Registration of securities for employees (post-effective amendment)
5:26pm
25-NSE
h2jkx766
22 Feb 24
Exchange delisting
9:01am
6-K
3j51o zqhw
22 Feb 24
Gracell Biotechnologies Acquisition Completed
8:50am
6-K
hm3oo14
20 Feb 24
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
8:22am
6-K
iqqp8nb88tsq4dx12
30 Jan 24
Gracell Biotechnologies Announces FDA Clearance of IND Application
6:02am
6-K
lnlrj fznd7jidmhky
17 Jan 24
Current report (foreign)
4:30pm
6-K
22sdidf2per5mlwfume9
8 Jan 24
Current report (foreign)
4:01pm
6-K
tfmacxmyo
29 Dec 23
Current report (foreign)
6:51pm
6-K
udtnrybc1n3xza
26 Dec 23
Voting and Support Agreement
8:12am
6-K
p907fi
22 Dec 23
Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States
6:03am
6-K
6e5yoax 9o9
18 Dec 23
Current report (foreign)
4:00pm
6-K
ovh5ymktlgzs16do3g
14 Nov 23
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update
6:04am
6-K
a1p1vp5ip9i6 hf
29 Sep 23
Current report (foreign)
6:09am
6-K
nqftjyx
27 Sep 23
Current report (foreign)
6:16am